epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-214, Phase III. Recruiting

Heart failure with reduced ejection fraction

CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Contoso Pharmaceuticals (fictional), Phase III, Cardiovascular. Month 0 is September 2023.
Randomise 824 (drop-out 15%) and screen about 1499 (screen failure 45%)
Mar 2027
Confidence wanted
Sites per country
Edit the site counts in the table below
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Feb 2028month 53.8
  • Fast case (P10)Apr 2027month 43.7
  • Slow case (P90)Jun 2029month 69.2
  • Chance of meeting the deadline7%wanted 85%
  • Sites12010% likely to recruit nobody
  • Patients to screen1,499to randomise 824

Likely to finish in February 2028, 12 months after the deadline

EPI-214, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow caseActual
Sep 20230000
Mar 20244205
Sep 202470503542
Mar 2025202152111147
Sep 2025346265194242
Mar 2026491378278352
Sep 2026638491362456
Mar 2027784601446–
Sep 2027824714528–
Mar 2028824824613–
Sep 2028824824697–
Mar 2029824824780–
Sep 2029824824824–
Mar 2030824824824–

Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.

How likely is it to finish by a given month?

About a one-in-ten chance of finishing by March 2027

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 7 of 100 dots finish in time

Drag the handle or
In time: 7%Median Mar 2028Late: 93%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
Sep 20230%
Mar 20240%
Sep 20240%
Mar 20250%
Sep 20250%
Mar 20260%
Sep 20260%
Mar 20277%
Sep 202725%
Mar 202850%
Sep 202872%
Mar 202986%
Sep 202993%
Mar 203097%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.122
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×0.75 United States
  • Site type: ×0.988 Usual mix in United States
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 4.1 to 10.2 100224
United Kingdom
0.136
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.975 Usual mix in United Kingdom
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 4.0 to 10.0 4495
Spain
0.161
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×1 Spain
  • Site type: ×0.977 Usual mix in Spain
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 7.6 to 13.6 71137
Poland
0.237
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×1.4 Poland
  • Site type: ×1.028 Usual mix in Poland
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 11.1 to 17.1 41184
Turkey
0.159
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×1 Turkey
  • Site type: ×0.965 Usual mix in Turkey
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 1870
India
0.173
  • Therapeutic area: 0.300 Cardiovascular baseline
  • Country: ×1.1 India
  • Site type: ×0.952 Usual mix in India
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 15114

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Turkey

Four sourced risks

  • All sites

    Ethics committees fell from 145 to 49 in 2024, cutting review capacity.

    Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B

    Tightens: site activation overdue

  • All sites

    A fixed pharmaceutical exchange rate has caused repeated medicine shortages.

    Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D

    Tightens: study drug at the site

  • All sites

    Start-up time has not been measured since CRO data from 2014 and 2015.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

  • If it recurs

    Sites in the south-east lie in the 2023 earthquake zone.

    Major earthquake in a site region · SH-11 · grade C

India

Two sourced risks

  • All sites

    Vulnerable participants in trials of new drugs need an audio-visual record of their consent.

    Mandatory audio-visual consent for all participants · RW-03 · grade C

    Tightens: consent findings

  • All sites

    Start-up time is unmeasured beyond the statutory 90 working days.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

    Tightens: site activation overdue

Risk-register entries; the choice of entries per country is epiClinical's.